Sygnature takes immense pride in its numerous accomplishments, fruitful research partnerships, and well-deserved awards. It is with great pleasure that we share these remarkable achievements at every available opportunity. Contained herein, you will have the opportunity to explore and be informed about the latest and most thrilling advancements taking place within our organization.
Filter by:
9th October 2024
News
Sygnature Discovery has Chosen Elsevier as New Preferred Partner to Empower its Global Team of Chemists
3rd October 2024
News
Sygnature Discovery Strengthens Leadership Team with Amira Modi as Chief Operating Officer and Board Member
26th September 2024
News
Sygnature Discovery Unlocks Life-Changing Treatment Options with New Human Disease Modeling Platform
20th August 2024
News
Sygnature Discovery boosts North American growth with new General Manager
30th April 2024
News
Sygnature Discovery Receives EcoVadis Award For Sustainable Excellence
23rd April 2024
News
Sygnature Discovery goes for global industry recognition with Chief Scientific Officer hire
29th November 2023
News
First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer
13th November 2023
News
Sygnature Discovery Appoints Industry Leaders To Board Of Directors
2nd November 2023
News
Sygnature Discovery invests £3.75M in Compound Management to provide cutting-edge hit finding capabilities to pharma and biotechnology customers
10th October 2023
News
Sygnature Discovery collaborates with Axol Bioscience to utilize human iPSC-derived microglial cells in high-content imaging drug discovery screening workflows.
25th September 2023
News Targeted Protein Degradation
Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds
14th September 2023
News
Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment